[go: up one dir, main page]

FR2834991B1 - Nouveaux anticorps anti-igf-ir et leurs applications - Google Patents

Nouveaux anticorps anti-igf-ir et leurs applications

Info

Publication number
FR2834991B1
FR2834991B1 FR0205753A FR0205753A FR2834991B1 FR 2834991 B1 FR2834991 B1 FR 2834991B1 FR 0205753 A FR0205753 A FR 0205753A FR 0205753 A FR0205753 A FR 0205753A FR 2834991 B1 FR2834991 B1 FR 2834991B1
Authority
FR
France
Prior art keywords
igf
antibodies
applications
new anti
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0205753A
Other languages
English (en)
Other versions
FR2834991A1 (fr
Inventor
Liliane Goetsch
Olivier Leger
Nathalie Corvaia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0200653A external-priority patent/FR2834990A1/fr
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to FR0205753A priority Critical patent/FR2834991B1/fr
Priority to AT03712270T priority patent/ATE357460T1/de
Priority to PCT/FR2003/000178 priority patent/WO2003059951A2/fr
Priority to DK03712270T priority patent/DK1461359T3/da
Priority to ES03712270T priority patent/ES2283759T3/es
Priority to CNB038024489A priority patent/CN100410275C/zh
Priority to BRPI0306973A priority patent/BRPI0306973B8/pt
Priority to CA2473039A priority patent/CA2473039C/fr
Priority to EP06126429A priority patent/EP1798242B1/fr
Priority to MXPA04006980A priority patent/MXPA04006980A/es
Priority to PT03712270T priority patent/PT1461359E/pt
Priority to JP2003560053A priority patent/JP4606739B2/ja
Priority to SI200330732T priority patent/SI1461359T1/sl
Priority to HK05110480.1A priority patent/HK1078590B/xx
Priority to DE60312639T priority patent/DE60312639T2/de
Priority to ES06126430T priority patent/ES2427964T3/es
Priority to EP06126430.5A priority patent/EP1806364B1/fr
Priority to EP03712270A priority patent/EP1461359B1/fr
Priority to AU2003216748A priority patent/AU2003216748B2/en
Publication of FR2834991A1 publication Critical patent/FR2834991A1/fr
Priority to US10/735,916 priority patent/US7241444B2/en
Priority to ZA2004/05402A priority patent/ZA200405402B/en
Priority to US11/012,353 priority patent/US7553485B2/en
Application granted granted Critical
Publication of FR2834991B1 publication Critical patent/FR2834991B1/fr
Priority to US11/783,513 priority patent/US7914784B2/en
Priority to US11/783,666 priority patent/US20080063639A1/en
Priority to US11/801,080 priority patent/US20080193445A1/en
Priority to CY20071100801T priority patent/CY1106662T1/el
Priority to US12/388,534 priority patent/US8101180B2/en
Priority to AU2009201674A priority patent/AU2009201674B2/en
Priority to JP2010124341A priority patent/JP2010233575A/ja
Priority to US13/037,734 priority patent/US8168410B2/en
Priority to US13/352,599 priority patent/US8808999B2/en
Priority to US13/777,040 priority patent/US20130273031A1/en
Priority to US14/492,636 priority patent/US20150079080A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR0205753A 2002-01-18 2002-05-07 Nouveaux anticorps anti-igf-ir et leurs applications Expired - Fee Related FR2834991B1 (fr)

Priority Applications (33)

Application Number Priority Date Filing Date Title
FR0205753A FR2834991B1 (fr) 2002-01-18 2002-05-07 Nouveaux anticorps anti-igf-ir et leurs applications
AU2003216748A AU2003216748B2 (en) 2002-01-18 2003-01-20 Novel anti-IGF-IR antibodies and uses thereof
BRPI0306973A BRPI0306973B8 (pt) 2002-01-18 2003-01-20 anticorpos anti-igf-ir, seu método de produção e seus usos, hibridoma murino, ácido nucléico isolado, vetor, composição, kit ou conjunto, e método diagnóstico in vitro de doenças induzidas por uma superexpressão ou uma subexpressão do receptor igf-ir
DK03712270T DK1461359T3 (da) 2002-01-18 2003-01-20 Hidtil ukendte anti-IGF-IR-antistoffer og anvendelser deraf
ES03712270T ES2283759T3 (es) 2002-01-18 2003-01-20 Anticuerpos anti-igf-ir y sus aplicaciones.
CNB038024489A CN100410275C (zh) 2002-01-18 2003-01-20 新的抗igf-ir抗体及其应用
DE60312639T DE60312639T2 (de) 2002-01-18 2003-01-20 Antikörper gegen igf-ir und ihre verwendungen
CA2473039A CA2473039C (fr) 2002-01-18 2003-01-20 Nouveaux anticorps anti-igf-ir et leurs applications
EP06126429A EP1798242B1 (fr) 2002-01-18 2003-01-20 Anticorps anti-IGF-IR et leurs applications
MXPA04006980A MXPA04006980A (es) 2002-01-18 2003-01-20 Anticuerpos novedosos anti-receptor del factor de crecimiento i tipo insulina, y usos de los mismos.
PT03712270T PT1461359E (pt) 2002-01-18 2003-01-20 Anticorpos anti-igf-ir e suas aplicações
JP2003560053A JP4606739B2 (ja) 2002-01-18 2003-01-20 新規抗ｉｇｆ−ｉｒ抗体およびその使用
SI200330732T SI1461359T1 (sl) 2002-01-18 2003-01-20 Nova anti IGF-IR protitelesa in njihova uporaba
HK05110480.1A HK1078590B (en) 2002-01-18 2003-01-20 Novel anti-igf-ir antibodies and uses thereof
PCT/FR2003/000178 WO2003059951A2 (fr) 2002-01-18 2003-01-20 Anticorps anti-igf-ir et leurs applications
ES06126430T ES2427964T3 (es) 2002-01-18 2003-01-20 Nuevos anticuerpos anti-IGF-IR y sus aplicaciones
EP06126430.5A EP1806364B1 (fr) 2002-01-18 2003-01-20 Nouveaux anticorps anti-igf-ir et leurs applications
EP03712270A EP1461359B1 (fr) 2002-01-18 2003-01-20 Anticorps anti-igf-ir et leurs applications
AT03712270T ATE357460T1 (de) 2002-01-18 2003-01-20 Antikörper gegen igf-ir und ihre verwendungen
US10/735,916 US7241444B2 (en) 2002-01-18 2003-12-16 Anti-IGF-IR antibodies and uses thereof
ZA2004/05402A ZA200405402B (en) 2002-01-18 2004-07-07 Novel anti-igf-ir antibodies and uses thereof
US11/012,353 US7553485B2 (en) 2002-01-18 2004-12-16 Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US11/783,513 US7914784B2 (en) 2002-01-18 2007-04-10 Anti-IGF-IR antibodies and uses thereof
US11/783,666 US20080063639A1 (en) 2002-01-18 2007-04-11 Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
US11/801,080 US20080193445A1 (en) 2002-01-18 2007-05-08 Novel anti-IGF-IR antibodies and uses thereof
CY20071100801T CY1106662T1 (el) 2002-01-18 2007-06-15 Αντι-igf-ir αντισωματα και οι εφαρμογες τους
US12/388,534 US8101180B2 (en) 2002-01-18 2009-02-19 Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
AU2009201674A AU2009201674B2 (en) 2002-01-18 2009-04-24 Novel anti-IGF-IR antibodies and uses thereof
JP2010124341A JP2010233575A (ja) 2002-01-18 2010-05-31 新規抗ｉｇｆ−ｉｒ抗体およびその使用
US13/037,734 US8168410B2 (en) 2002-01-18 2011-03-01 Anti-IGF-IR antibodies and uses thereof
US13/352,599 US8808999B2 (en) 2002-01-18 2012-01-18 Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US13/777,040 US20130273031A1 (en) 2002-01-18 2013-02-26 Novel anti-igf-ir antibodies and uses thereof
US14/492,636 US20150079080A1 (en) 2002-01-18 2014-09-22 Novel anti-igf-ir antibodies and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0200653A FR2834990A1 (fr) 2002-01-18 2002-01-18 Nouveaux anticorps anti-igf-ir et leurs applications
FR0205753A FR2834991B1 (fr) 2002-01-18 2002-05-07 Nouveaux anticorps anti-igf-ir et leurs applications

Publications (2)

Publication Number Publication Date
FR2834991A1 FR2834991A1 (fr) 2003-07-25
FR2834991B1 true FR2834991B1 (fr) 2004-12-31

Family

ID=27624205

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0205753A Expired - Fee Related FR2834991B1 (fr) 2002-01-18 2002-05-07 Nouveaux anticorps anti-igf-ir et leurs applications

Country Status (1)

Country Link
FR (1) FR2834991B1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7667021B2 (en) 2002-05-24 2010-02-23 Schering Corporation Neutralizing human anti-IGFR antibody

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938428A (zh) 2003-11-12 2007-03-28 先灵公司 多基因表达的质粒系统
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
ES2356830T3 (es) 2004-12-03 2011-04-13 Schering Corporation Biomarcadores para preselección de pacientes para terapia de anti-igf-1r.
ES2427924T3 (es) 2006-06-30 2013-11-04 Merck Sharp & Dohme Corp. Biomarcador IGFBP2
US20110262525A1 (en) 2006-12-13 2011-10-27 Schering Corporation Methods of treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0110927A (pt) * 2000-05-19 2003-03-11 Scancell Ltd Anticorpo, ácido nucléico, vetor, célula, método de fabricar um anticorpo, composição farmacêutica, uso de um anticorpo ou de um ácido nucleico, e, método para o tratamento ou profilaxia do câncer
AR032028A1 (es) * 2001-01-05 2003-10-22 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7667021B2 (en) 2002-05-24 2010-02-23 Schering Corporation Neutralizing human anti-IGFR antibody

Also Published As

Publication number Publication date
FR2834991A1 (fr) 2003-07-25

Similar Documents

Publication Publication Date Title
FR2888850B1 (fr) Nouveaux anticorps anti-igf-ir et leurs applications
CY2018009I2 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
EP1812062A4 (fr) Anticorps anti-addl et leurs utilisations
DK2418220T3 (da) Interferon-alpha-antistoffer og anvendelser deraf
EP1587482A4 (fr) Compositions anti-inflammatoires et leurs utilisations
EP1638977A4 (fr) Salinosporamides et leurs methodes d'utilisation
DK1390389T3 (da) Cripto-blokerende antistoffer og anvendelser deraf
DK1610820T3 (da) Høj-koncentration antistof- og proteinformuleringer
EP1578947A4 (fr) Anticorps diriges contre la phospholipase a2 et utilisations
EP1562968A4 (fr) Anticorps anti-il-6, compositions, methodes et utilisations associees
DE602004021904D1 (de) Gyraseinhibitoren und deren verwendungen
EP1298180A4 (fr) Composition hydrofuge et oleofuge
IS2504B (is) Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
EP1396500A4 (fr) Anticorps anti-trail-r
EP1692287A4 (fr) Agressines bacteriennes et utilisations
EP1427832A4 (fr) Genes de methyltransferase et leurs utilisations
EP1392106A4 (fr) Genes tyra et utilisations associees
EP1562627A4 (fr) Conjugues de corticosteroides et utilisations de ceux-ci
EP1638513A4 (fr) Substances insaponifiables en teneur elevee et leurs procedes d'utilisation
EP1689781A4 (fr) Anticorps de clycoformes de cd44 et utilisations de ceux-ci
EP1478761A4 (fr) Degradation de pesticides et de toxines esteriques hydrophobes
PL361518A1 (pl) Zastosowanie substancji oraz kompozycja farmaceutyczna
EP1633749A4 (fr) Composes de deazaflavine et leurs methodes d'utilisation
FR2834991B1 (fr) Nouveaux anticorps anti-igf-ir et leurs applications
EP1633310A4 (fr) Analogues de thiotungstate et leurs utilisations

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20160129